Program
aflutinib
Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.
Drug pageAflutinib: every studyMany companies study it; this page follows only the 21 they lead. All 63 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allist Pharmaceuticals | 114 open or running | phase 3since Apr 12, 2021 | Nov 21, 2016 | Dec 2026phase 3 · NCT04853342 |
| Beijing Aosaikang Pharmaceuticalits history only | 41 open or running | phase 3since Oct 12, 2019 | Apr 10, 2018 | none ahead |
| ArriVent BioPharmaits history only | 33 open or running | phase 3since Oct 31, 2022 | Apr 6, 2022 | Feb 2029phase 3 · NCT07185997 |
| Abbisko Caymanits history only | 11 open or running | phase 2since Oct 30, 2024 | Oct 30, 2024 | Dec 30, 2027phase 2 · NCT06668103 |
| Alphamab Oncologyits history only | 11 open or running | phase 1since Mar 5, 2025 | Mar 5, 2025 | Jun 30, 2028phase 1 · NCT06868732 |
| MediLink Therapeutics (Suzhou)its history only | 11 open or running | phase 2since Sep 3, 2025 | Sep 3, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Allist Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 21, 2016First study: phase 1 study in NSCLCFirst studyNCT02973763 · 14 enrolled
- Apr 18, 2017No phase study in Advanced NSCLCNCT03127449 · 116 enrolled · China
- Feb 26, 2018Phase 2 study in Advanced NSCLC Patients With T790MNCT03452592 · 220 enrolled · China
- Apr 23, 20192 phase 1 studies in Healthy Male VolunteersNCT03926182, NCT03941340
- Apr 12, 2021Phase 1 study in NSCLCNCT04858958 · 90 enrolled · China
- Apr 12, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04853342 · 318 planned · China
- Jul 5, 2021Phase 1 study in NSCLCNCT04958967 · China
- Jul 14, 2022Phase 2 study in NSCLCNCT05466149 · 100 enrolled · China
- Apr 9, 2025Phase 3 study in NSCLC Patients With Brain MetastasisNCT06970639 · 380 planned · China
- May 20, 2025Phase 3 study in NSCLCNCT07010419 · 338 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT04853342
- Oct 31, 2028Primary completion: phase 3 study in NSCLCNCT07010419
- Mar 2029Primary completion: phase 3 study in NSCLC Patients With Brain MetastasisNCT06970639
TargetBeta
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 11 Allist Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07010419NSCLC · China | 3 | Recruiting | Oct 31, 2028 | 338 |
| NCT06970639NSCLC Patients With Brain Metastasis · China | 3 | Recruiting | Mar 2029 | 380 |
| NCT05466149NSCLC · China | 2 | Active, not recruiting | Jun 27, 2025 | 100 |
| NCT04958967NSCLC · China | 1 | Withdrawn | May 1, 2022 | 0 |
| NCT04858958NSCLC · China | 1 | Completed | Dec 5, 2024 | 90 |
| NCT04853342Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Dec 2026 | 318 |
| NCT03941340Healthy Male Volunteers · China | 1 | Completed | Sep 6, 2019 | 6 |
| NCT03926182Healthy Male Volunteers · China | 1 | Completed | Apr 3, 2019 | 16 |
| NCT03452592Advanced NSCLC Patients With T790M · China | 2 | Terminated | Apr 21, 2021 | 220 |
| NCT03127449Advanced NSCLC · China | – | Terminated | May 12, 2021 | 116 |
| NCT02973763NSCLC | 1 | Terminated | Feb 4, 2021 | 14 |
How it is read
Names in the registry
- “Furmonertinib”, 6 entries
- “Alflutinib”, 3 entries
- “ASK120067”, 3 entries
- “Firmonertinib”, 2 entries
- “Furmonertinib 160mg”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasm Metastasis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.